Security Reports > Flexion Therapeutics
Flexion Therapeutics
Data Breaches, Cyber Attacks and Security Report
https://flexiontherapeutics.com ᛫
Last updated May 26, 2020
https://flexiontherapeutics.com ᛫
Last updated May 26, 2020
UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Flexion Therapeutics is implementing good security practices.
Flexion Therapeutics is an American pharmaceutical company based in Burlington, Massachusetts that is developing reformulated sustained release versions of existing drugs that are intended to be injected into the joint to treat osteoarthritis.It was founded around 2007 by two former Eli Lilly & Co. executives and went public in 2014.In November 2016 the FDA accepted Flexion's New Drug Application for FX006, a sustained-release formulation of triamcinolone acetonide (a corticosteroid), branded "Zilretta".
This report shows a preliminary security rating for Flexion Therapeutics. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.
Get a deeper scan →Read more about the latest issues in cybersecurity
Compare Flexion Therapeutics's security performance with other companies